Halozyme Therapeutics, Inc. (HALO) on Decifer

Decifer ranks HALO number 1 of 265 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 24% and it turns most of its profit into real cash.
• Revenue is growing about 38% a year, profits are expected to grow 22%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• A single chokepoint for specialty biologics with returns near 24 percent, revenue growth of 38 percent, and momentum of 30 out of 35 above trend is highly investible.

The current read

The evidence on HALO lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full HALO research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.